Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 121

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 121
---
 and failure to comply with Swiss or Nasdaq requirements could lead to delisting; •Even if the Merger is completed, there is no guarantee that any proceeds will be paid to our shareholders under the CVR Agreement; •The unaudited pro forma condensed consolidated financial information included in this proxy statement/prospectus is presented for illustrative purposes only and may not reflect our actual operating results or financial condition following the Merger; •We must obtain regulatory approvals before commercializing our products, and clinical trial data may not meet FDA or European Medicines Agency, or the EMA requirements, potentially causing delays or additional study obligations; •Our failure to meet the continued listing requirements Nasdaq could result in a delisting of our securities or us seeking to transfer our listed securities to a different exchange; •As a “foreign private issuer” and emerging growth company, or EGC, we benefit from reduced SEC and Nasdaq requirements, which may offer less investor protection and impact market confidence; 19 •We have identified material weaknesses in our internal control, and ineffective remediation could impair financial reporting and investor confidence; •As a Swiss stock corporation, we are governed by Swiss law, which may limit shareholder rights, pre -emptiveparticipation in future issuances, and the ability of U.S. shareholders to enforce judgments; •The registration of share capital increases or decreases in the Swiss commercial register may be delayed or blocked, and shareholder resolutions approving capital changes may be subject to challenge; •Our Common Shares are not listed on a Swiss exchange, and as a result, the Swiss takeover regime does not apply to us; •As a Swiss stock corporation, our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends, and otherwise manage ongoing capital needs; •Following the Merger, we may lose our foreign private issuer status, triggering U.S. domestic reporting requirements and increased compliance costs; •Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of NLS Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kadimastem; •The Merger is subject to the satisfaction or waiver of conditions that may not be satisfied or completed on a timely basis, if at all. Failure to consummate the Merger could adversely affect the future business and financial results of NLS; •NLS will have limited protection in the event that any of the representations and warranties made by Kadimastem ultimately proves to be inaccurate or incorrect; •Laws